Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2015

01-08-2015 | Preclinical study

Assessment of HER2 status in invasive breast cancers with increased centromere 17 copy number

Authors: Min Hye Jang, Eun Joo Kim, Hyun Jeong Kim, Yul Ri Chung, So Yeon Park

Published in: Breast Cancer Research and Treatment | Issue 1/2015

Login to get access

Abstract

This study was designed to evaluate usefulness of additional fluorescence in situ hybridization (FISH) using other reference genes on chromosome 17 for assessment of HER2 status in invasive breast cancers with increased centromere 17 copy number, and to compare this approach with conventional methods based on the 2007 and 2013 ASCO/CAP guidelines. We performed FISH with probes for SMS, RARA, and TP53 on 253 breast cancers with centromeric probe CEP17 copy number ≥2.6 using tissue microarrays. If one or more gene had a mean copy number <2.6, the largest number for that gene(s) was chosen as an alternative to CEP17 copy number. Of the 243 cases in which re-grading was possible, only 2 had copy numbers ≥2.6 for RARA, SMS, and TP53. Of the 151 breast cancers which were considered HER2 non-amplified by the 2007 ASCO/CAP guidelines using the HER2:CEP17 ratio, 42 (27.8 %) were re-graded as amplified and 33 (21.8 %) as equivocal after FISH using additional reference genes. Of the 101 HER2-non-amplified cases by the 2013 ASCO/CAP guidelines, 2 (2.0 %) were reclassified as amplified and 24 (23.8 %) as equivocal. Of 46 equivocal cases, 35 (76.1 %) were re-graded as amplified. After re-grading, HER2-amplified cases were significantly increased, and the concordance between HER2 FISH and HER2 immunohistochemistry decreased. And some pathologic features of the cases which were designated to have HER2 amplification after additional FISH were not compatible with those of HER2-amplified breast cancers. The use of additional reference genes has been suggested as an option for accurate assessment of HER2 status in breast cancers with increased CEP17 copy number. However, this has limitations in that it can cause over-grading of HER2 status in tumors that lose the new reference genes. Thus, at present, it seems that additional FISH using other reference gene such as SMS, RARA, and TP53 for the cases with increased CEP17 copy number is not suitable for daily practice.
Appendix
Available only for authorised users
Literature
1.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (New York, NY) 235(4785):177–182CrossRef
2.
Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL (1989) HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 7(8):1120–1128PubMed
3.
Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF, American Society of Clinical O, College of American P (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25(1):118–145. doi:10.​1200/​JCO.​2006.​09.​2775 CrossRefPubMed
4.
Dal Lago L, Durbecq V, Desmedt C, Salgado R, Verjat T, Lespagnard L, Ma Y, Veys I, Di Leo A, Sotiriou C, Piccart M, Larsimont D (2006) Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. Mol Cancer Ther 5(10):2572–2579. doi:10.​1158/​1535-7163.​MCT-06-0129 CrossRefPubMed
5.
Tse CH, Hwang HC, Goldstein LC, Kandalaft PL, Wiley JC, Kussick SJ, Gown AM (2011) Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy. J Clin Oncol 29(31):4168–4174. doi:10.​1200/​JCO.​2011.​36.​0107 CrossRefPubMed
6.
7.
Gunn S, Yeh IT, Lytvak I, Tirtorahardjo B, Dzidic N, Zadeh S, Kim J, McCaskill C, Lim L, Gorre M, Mohammed M (2010) Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity. BMC Cancer 10:396. doi:10.​1186/​1471-2407-10-396 PubMedCentralCrossRefPubMed
8.
Staaf J, Jonsson G, Ringner M, Vallon-Christersson J, Grabau D, Arason A, Gunnarsson H, Agnarsson BA, Malmstrom PO, Johannsson OT, Loman N, Barkardottir RB, Borg A (2010) High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer. Breast Cancer Res 12(3):R25. doi:10.​1186/​bcr2568 PubMedCentralCrossRefPubMed
9.
Wang S, Hossein Saboorian M, Frenkel EP, Haley BB, Siddiqui MT, Gokaslan S, Hynan L, Ashfaq R (2002) Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Mod Pathol 2:137–145. doi:10.​1038/​modpathol.​3880505 CrossRef
10.
Downs-Kelly E, Yoder BJ, Stoler M, Tubbs RR, Skacel M, Grogan T, Roche P, Hicks DG (2005) The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol 29(9):1221–1227CrossRefPubMed
11.
Liu Y, Ma L, Liu D, Yang Z, Yang C, Hu Z, Chen W, Yang Z, Chen S, Zhang Z (2014) Impact of polysomy 17 on HER2 testing of invasive breast cancer patients. Int J Clin Exp Pathol 7(1):163–173PubMedCentralPubMed
12.
Perez EA, Reinholz MM, Hillman DW, Tenner KS, Schroeder MJ, Davidson NE, Martino S, Sledge GW, Harris LN, Gralow JR, Dueck AC, Ketterling RP, Ingle JN, Lingle WL, Kaufman PA, Visscher DW, Jenkins RB (2010) HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol 28(28):4307–4315. doi:10.​1200/​JCO.​2009.​26.​2154 PubMedCentralCrossRefPubMed
13.
Downey L, Livingston RB, Koehler M, Arbushites M, Williams L, Santiago A, Guzman R, Villalobos I, Di Leo A, Press MF (2010) Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer. Clin Cancer Res 16(4):1281–1288. doi:10.​1158/​1078-0432.​CCR-09-1643 CrossRefPubMed
14.
Ma Y, Lespagnard L, Durbecq V, Paesmans M, Desmedt C, Gomez-Galdon M, Veys I, Cardoso F, Sotiriou C, Di Leo A, Piccart MJ, Larsimont D (2005) Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice. Clin Cancer Res 11(12):4393–4399. doi:10.​1158/​1078-0432.​CCR-04-2256 CrossRefPubMed
15.
Vanden Bempt I, Van Loo P, Drijkoningen M, Neven P, Smeets A, Christiaens MR, Paridaens R, De Wolf-Peeters C (2008) Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. J Clin Oncol 26(30):4869–4874. doi:10.​1200/​jco.​2007.​13.​4296 CrossRefPubMed
16.
17.
18.
19.
Yeh IT, Martin MA, Robetorye RS, Bolla AR, McCaskill C, Shah RK, Gorre ME, Mohammed MS, Gunn SR (2009) Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event. Mod Pathol 9:1169–1175. doi:10.​1038/​modpathol.​2009.​78 CrossRef
20.
Moelans CB, de Weger RA, van Diest PJ (2010) Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification. Breast Cancer Res Treat 120(1):1–7. doi:10.​1007/​s10549-009-0539-2 CrossRefPubMed
21.
Marchio C, Lambros MB, Gugliotta P, Di Cantogno LV, Botta C, Pasini B, Tan DS, Mackay A, Fenwick K, Tamber N, Bussolati G, Ashworth A, Reis-Filho JS, Sapino A (2009) Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol 219(1):16–24. doi:10.​1002/​path.​2574 CrossRefPubMed
22.
Troxell ML, Bangs CD, Lawce HJ, Galperin IB, Baiyee D, West RB, Olson SB, Cherry AM (2006) Evaluation of Her-2/neu status in carcinomas with amplified chromosome 17 centromere locus. Am J Clin Pathol 126(5):709–716. doi:10.​1309/​9EYM-6VE5-8F2Y-CD9F CrossRefPubMed
23.
Varga Z, Tubbs RR, Wang Z, Sun Y, Noske A, Kradolfer D, Bosshard G, Jochum W, Moch H, Ohlschlegel C (2011) Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer. Breast Cancer Res Treat. doi:10.​1007/​s10549-011-1642-8
24.
Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF, American Society of Clinical O, College of American P (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clinl Oncol 31(31):3997–4013. doi:10.​1200/​JCO.​2013.​50.​9984 CrossRef
25.
Broad Institute TCGA Genome Data Analysis Center (2015) SNP6 Copy number analysis (GISTIC2). Broad Institute of MIT and Harvard. doi:10.​7908/​C1W37V8R
26.
Hanna WM, Ruschoff J, Bilous M, Coudry RA, Dowsett M, Osamura RY, Penault-Llorca F, van de Vijver M, Viale G (2014) HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. Mod Pathol 1:4–18. doi:10.​1038/​modpathol.​2013.​103 CrossRef
27.
28.
Paroni G, Fratelli M, Gardini G, Bassano C, Flora M, Zanetti A, Guarnaccia V, Ubezio P, Centritto F, Terao M, Garattini E (2012) Synergistic antitumor activity of lapatinib and retinoids on a novel subtype of breast cancer with coamplification of ERBB2 and RARA. Oncogene 31(29):3431–3443. doi:10.​1038/​onc.​2011.​506 CrossRefPubMed
29.
Dubourg C, Bonnet-Brilhault F, Toutain A, Mignot C, Jacquette A, Dieux A, Gerard M, Beaumont-Epinette MP, Julia S, Isidor B, Rossi M, Odent S, Bendavid C, Barthelemy C, Verloes A, David V (2014) Identification of nine new RAI1-truncating mutations in smith-magenis syndrome patients without 17p11.2 deletions. Mol Syndromol 5(2):57–64. doi:10.​1159/​000357359 PubMedCentralPubMed
30.
31.
Kasiappan R, Shih HJ, Chu KL, Chen WT, Liu HP, Huang SF, Choy CO, Shu CL, Din R, Chu JS, Hsu HL (2009) Loss of p53 and MCT-1 overexpression synergistically promote chromosome instability and tumorigenicity. Mol Cancer Res 7(4):536–548. doi:10.​1158/​1541-7786.​MCR-08-0422 CrossRefPubMed
Metadata
Title
Assessment of HER2 status in invasive breast cancers with increased centromere 17 copy number
Authors
Min Hye Jang
Eun Joo Kim
Hyun Jeong Kim
Yul Ri Chung
So Yeon Park
Publication date
01-08-2015
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2015
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-015-3522-0

Other articles of this Issue 1/2015

Breast Cancer Research and Treatment 1/2015 Go to the issue

Epidemiology

Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer

Preclinical study

Increased COX-2 expression in epithelial and stromal cells of high mammographic density tissues and in a xenograft model of mammographic density

Epidemiology

Reduction of global 5-hydroxymethylcytosine is a poor prognostic factor in breast cancer patients, especially for an ER/PR-negative subtype

Clinical trial

A proposal for a new classification of T4 breast cancer as stage IIIC: a report from the Korean Breast Cancer Society

Preclinical Study

Localized experimental bone metastasis drives osteolysis and sensory hypersensitivity at distant non-tumor-bearing sites

Preclinical Study

Loss of protein tyrosine phosphatase, non-receptor type 2 is associated with activation of AKT and tamoxifen resistance in breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits